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Abstract
Patients with cystic ﬁbrosis (CF) are at risk of developing low bone mineral density (BMD) and fragility fractures. This paper presents
consensus statements that summarise current knowledge of the epidemiology and pathophysiology of CF-related skeletal deﬁcits and provides
guidance on its assessment, prevention and treatment. The statements were validated using a modiﬁed Delphi methodology.
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1. Introduction
It is now widely recognised that people with cystic ﬁbrosis
(CF) are at increased risk of developing low bone mineral
density (BMD) and sustaining a low trauma fracture. The
purpose of this EuroCareCF-funded work package was to
develop consensus statements that (a) summarise current
knowledge of the epidemiology and pathophysiology of CF-
related low BMD and (b) provide guidance on its assessment,
prevention and treatment.
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2. Methods
A list of topics was deﬁned by a core group and a com-
prehensive search undertaken for published and unpublished
literature on these topics by a working group of clinicians
with a research interest in CF bone disorders from Europe
and North America. After completing this process, statements
were drafted by the working group at a meeting in Paris in
June 2009 and graded according to the recommendations of
the Scottish Intercollegiate Guidelines Network [1].
Statements were grouped into general and speciﬁc risk
factors for CF bone disease, assessment of bone health,
prevention strategies for CF bone disease and treatment strate-
gies of CF bone disease. The statements for risk factors
and preventive/curative treatments were further divided into
nutrition, endocrine issues, calcium, vitamin D and vita-
min K therapies. Monitoring of glucocorticoids, indications
for and monitoring of bisphosphonate treatment were also
considered.
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European experts, selected according to their interest in
both CF and bone metabolism, were invited to participate
in the validation of the statements using a modiﬁed Delphi
methodology [2]. Participants were sent the list of statements
and asked whether they agreed, disagreed or were unable
to comment on each. If they disagreed they were asked to
provide a reason and an alternative statement. References
were also requested, in case trials had been overlooked in
the initial search strategy. The Delphi process was overseen
by two facilitators (I. Sermet-Gaudelus and C.S. Haworth)
whom sought further advice from experts on comments that
arose during the Delphi process. We determined that 80%
agreement would determine an adequate consensus on a
statement [3]. However, even if consensus was achieved,
comments were still considered and incorporated if it was felt




The quantity and quality of published trials on CF bone dis-
ease was considered poor. Most interventions were graded as
D (evidence from published case reports/series or expert opin-
ion). Statements were derived from experience in managing
patients with other bone diseases, especially postmenopausal
osteoporosis, but also from many forms of secondary osteo-
porosis, including in children. This was particularly necessary
for the statements relating to bone mineralisation assessment
with bone densitometry.
3.2. The modiﬁed Delphi process
The core group developed 82 statements, which were used
in Round One of the modiﬁed Delphi process. Thirty CF
specialists from Europe contributed to the modiﬁed Delphi
process. Consensus was not achieved for 30 statements in
Round 1 and these were subsequently modiﬁed by the
facilitators taking into account comments and suggestions
from the European CF specialists and the working group (ﬁve
statements were deleted, 25 statements were modiﬁed (two
of which were also merged). Eight statements were adjusted,
despite achieving consensus, as the facilitators considered that
this improved the quality of the statements. In Round 2 a
consensus was achieved for all statements (Table 1).
4. Discussion
The most controversial statements in Round 1 related to
(1) optimal vitamin D concentrations and supplementation
regimens; (2) the interpretation of bone densitometry data,
particularly in children and adolescents; and (3) the use of
bisphosphonates in children and adolescents.
4.1. Optimal vitamin D concentrations and supplementation
regimens
Serum 25-hydroxyvitamin D is the best biochemical
marker of vitamin D status, yet optimal lower and upper
thresholds for desirable levels in the CF population are still a
matter of debate. A threshold level of 20 ng/ml (50 nmol/l)
to prevent vitamin D deﬁciency has been suggested in the
current guidelines. A threshold of 20 ng/ml has also been
recommended by the Lawson Wilkins Pediatric Endocrine
Society based upon pediatric data available to date [4]. This
contrasts with the North American CF bone health con-
sensus statement which recommends achieving a minimum
25-hydroxyvitamin D concentration of 30ng/ml [5]. Higher
25-hydroxyvitamin D concentrations may offer extra skeletal
health beneﬁts including enhanced immune function and a
reduced risk of developing diabetes, cancer and cardiovascu-
lar disease [6]. However, no consensus has yet been reached
regarding the serum concentration of 25-hydroxyvitamin D
required to optimise bone mineralisation in children, adoles-
cents and young adults with or without CF. While it is clear
that patients with CF require vitamin D supplements and have
lower 25-hydroxyvitamin D levels and higher parathyroid
hormone (PTH) levels than healthy controls, cross-sectional
studies show no clear association between BMD and the
vitamin D status of patients with CF [7]. In addition, the 2
interventional studies so far performed show no effect on bone
mineralization and bone turnover markers [8,9]. Therefore,
current data show no evidence to demonstrate a beneﬁcial
effect of levels above 30 ng/ml (75 nmol/l) on bone mineral
density, fractures and markers of bone metabolism in people
with CF.
The 30 ng/ml cut-off proposed by Holick and colleagues
is designed to keep PTH levels as low as possible [10]. This
makes sense in elderly and adults as demineralisation may
result from increased bone resorption induced by elevated
PTH levels. This concept may not be valid in all situations,
as already demonstrated in patients with chronic renal insuf-
ﬁciency where too low PTH levels block bone formation and
induce the so called "adynamic bone disease". Along this line,
too low PTH levels may be detrimental in children and young
adults as it has been suggested that PTH levels in the high
normal range may favour bone formation [11]. Moreover, the
long term consequences of maintaining 25-hydroxyvitamin D
levels above 30ng/ml have not been extensively explored in
large groups of children or young adults.
Studies are also lacking to determine the most effective
vitamin D supplementation regimen to correct vitamin D
deﬁciency in people with CF [12]. However, recent data
suggest that 50,000 IU vitamin D3 (cholecalciferol) weekly
for 3 months may be a successful means of increasing
25-hydroxyvitamin D levels [13]. This study also suggests
that supplementation with vitamin D3 may achieve higher
levels of 25-hydroxyvitamin D than supplementation with
vitamin D2, a ﬁnding that has also been reported in the
general population [14]. However, potential failure of such
supplementation modality in patients with CF requires that in
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Table 1
Description and Pathophysiology of Bone Disease in CF
General Statements
1. Bone mineral content (BMC) and bone mineral density (BMD) are usually normal in children who have normal nutritional status and well preserved lung
function. However, several cross-sectional studies have found low BMC/BMD in children, possibly because of low bone mass accrual. Further
longitudinal studies are needed to conﬁrm these observations.
2. Reduced BMD is common in adolescents and adults. Longitudinal studies suggest lower peak bone mass accrual in adolescence, following which bone
loss may occur prematurely.
3. Adults have an increased risk of fracture compared to a healthy population of the same age and gender.
4. Transplant listed patients and transplant recipients usually have low BMD and are at risk of low trauma fracture.
5. In CF, low BMD results from an imbalance in bone remodeling with decreased bone formation and increased bone resorption, especially during infective
exacerbations.
6. Potential risk factors for CF bone disease include: poor nutritional status, lung infection, vitamin D insufﬁciency, vitamin K insufﬁciency, a negative
calcium balance, abnormal fatty acid status, hypogonadism, delayed puberty, CF related diabetes, glucocorticoid treatment, reduced levels of weight
bearing activity and the effect of CFTR dysfunction on bone cells.
Speciﬁc Risk Factors for CF Bone Disease
Nutritional status
7. There is a positive correlation between nutritional status and BMD.
8. Reduced lean body mass may contribute to reduced BMD.
Vitamin D
9. Vitamin D deﬁciency and insufﬁciency may result in impaired bone mineralisation and increased bone loss.
Vitamin K
10. Vitamin K deﬁciency may contribute to an alteration of the normal balance between bone formation and bone resorption. However, there is no evidence of
a direct link between vitamin K levels and BMD.
Calcium
11. Some studies suggest that people with CF are at increased risk of negative calcium balance that may adversely affect bone health.
Infection/systemic inﬂammation
12. Lung infection adversely affects bone health. There is an inverse relationship between BMD and the number of antibiotic courses, levels of serum C
reactive protein and serum interleukin 6.
Endocrine issues
13. Puberty is a key time for bone development. Peak growth velocity is associated with high bone mass accrual. Pubertal delay is common in children with
CF and may result in suboptimal bone acquisition.
Glucocorticoids
14. Continuous systemic glucocorticoid therapy is a signiﬁcant risk factor for bone loss and fracture, as it is in the general population. The effect increases
with daily dose and cumulative dose.
Assessment of Bone Health in CF
Dual Energy X-ray Absorptiometry Evaluation
15. Dual energy X-ray absorptiometry (DXA) is currently the gold standard method for measuring bone mineral content (BMC) and bone mineral density
(BMD) in people with CF.
16. DXA scans should be performed in centres experienced in interpreting BMD data from people with CF. Normative data should be age, gender and
geographically matched to the patients measured.
17. BMD should be measured at the total body and the lumbar spine in patients younger than 20 years of age, and at the lumbar spine and proximal hip in
patients of 20 years of age or older.
18. BMD values should be expressed as Z-scores* in premenopausal women and men under 50 years of age, and as T-scores in postmenopausal women and
in men 50 years of age or older. If Z-scores are not available, T-scores can be used in CF patients above 20 years of age. Until the age of 20, only the
Z-score can be used.
19. With DXA, BMD deﬁcits may be overestimated in patients with short stature, because they display a more severe decrease in bone area than in bone
mineral content.
20. For patients younger than 20 years of age whose height is at least 1 SD below age and sex matched healthy controls, BMD Z-scores should be adjusted
for height or statural age to avoid overestimating deﬁcits in BMD in people with short stature.
21. The term “CF related low BMD” may be applied to children and adults with a BMD Z-score below −2.
22. In CF children, adolescents or young adults up to the age of 20 years, osteoporosis is deﬁned as having a BMD Z score <−2 and a signiﬁcant fracture
history (low trauma fracture of a lower limb long bone, vertebral compression fracture, or two or more upper limb long bone fractures).
23. In postmenopausal women or men over the age of 50 years with CF, osteoporosis is deﬁned as having a BMD T-score ≤ −2.5. In younger adults,
osteoporosis is deﬁned as having a BMD Z score <−2 and a signiﬁcant fracture history. The term osteoporosis can also be applied to adults with CF
who have sustained a low trauma fracture as it is an indicator of increased bone fragility.
24. In children, routine bone density scans should ﬁrst be performed from around the age of eight to 10 years, and should be repeated approximately: every
ﬁve years if the BMD Z-score is >−1; every two years if the Z-score is between −1 and −2; and every year if the Z-score is <−2 or if the child has
experienced low trauma fractures. Bone density measurements can be ﬁrst done at an earlier age and/or yearly in children with signiﬁcant risk factors for
low BMD and in children before prescribing speciﬁc treatments for low BMD.
* The Z-score is the difference (expressed as the number of Standard Deviations) between a patient’s bone mineral density value and the average value of an
age- and gender-matched healthy population. The T-score is the difference (expressed as the number of SD) between a patient’s bone mineral density and the
average value of a population of healthy young adults of the same sex.
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Table 1 (continued)
25. In adults with CF less than 50 years of age, routine bone density scans are recommended approximately: every ﬁve years if the BMD Z-score is >−1;
every two years if the Z-score is between −1 and −2; every year if the Z-score is <−2. BMD measurements can be done yearly in adults with signiﬁcant
risk factors for low BMD. BMD measurements must be done before prescribing bone protective therapy.
26. In adults after 50 years of age, routine bone density scans are recommended approximately: every ﬁve years if the T-score is >−1; every two years if the
T-score is between −1 and −2.5; every year if the T-score is <−2.5. BMD measurements can be done yearly in adults with signiﬁcant risk factors for
low BMD. BMD measurements must be done before prescribing bone protective therapy.
27. Fracture history should be included in the medical record.
28. Vertebral fractures are often under-diagnosed. Chest X-rays should be routinely examined for the presence of vertebral fractures.
29. Vertebral fracture evaluation should be performed using lateral thoracolumbar spine X-rays in patients with low BMD, height loss and/or back pain.
Vertebral fracture diagnosis should be based on visual evaluation and the assessment of grade/severity of vertebral deformity. The Genant visual
semi-quantitative method is the current clinical technique of choice for diagnosing vertebral fracture with X-ray and with DXA morphometry.
Nutrition
30. In children, height must be recorded at every clinic and in-patient hospital visit and plotted on the appropriate percentile chart.
31. In adults height must be recorded at every clinic and inpatient hospital visit until growth has ceased and annually thereafter.
32. In children and adults, weight must be recorded at every clinic and in-patient hospital visit. In adults, weight and height measurements should be
converted to body mass index (kg/m2). In children over 2 years, BMI measurements should be plotted on the appropriate percentile chart and expressed as
either percentile positions or standard deviation scores.
33. There should be periodic assessment (at least annually) of dietary energy, protein and calcium intake by a dietitian experienced in the management of
patients with CF. This should be assessed more frequently in case of abnormal growth velocity or weight loss.
Vitamin D
34. Assessment of vitamin D status should include as a minimum: serum 25-hydroxyvitamin D, serum calcium, serum phosphorus and parathyroid hormone
concentrations. Optimally, urinary calcium excretion should be measured (either as the quantity of calcium in the total daily output (in mg/day) or as the
ratio calcium/creatinine on a morning urine sample) in patients prescribed vitamin D supplements.
35. The assay used to measure 25-hydroxyvitamin D should measure both vitamin D2 and vitamin D3 as this is essential to accurately determine vitamin D
status.
36. The 25-hydroxyvitamin D assay must adhere to internationally validated standards.
37. No consensus has yet been reached regarding the serum 25-hydroxyvitamin D concentration required to optimise bone mineralisation in children,
adolescents and young adults, with or without CF. Moreover, the long term consequences of maintaining 25-hydroxyvitamin D levels above 30 ng/ml
have not been extensively explored in large groups of children or young adults. To prevent vitamin D deﬁciency, we recommend a minimum
25-hydroxyvitamin D concentration of 20 ng/ml (50 nmol/l).
Calcium
38. There are no simple biochemical indicators of calcium status for use in clinical practice.
39. A specialist CF dietitian should assess calcium intake at least annually.
Vitamin K
40. Vitamin K status is best assessed by measuring serum concentrations of vitamin K1, PIVKA-II and under-carboxylated osteocalcin. If these are not
available, the prothrombin time can be measured, accepting that this is a less sensitive marker of vitamin K deﬁciency.
Endocrine assessment
41. Routine clinical visits should include accurate measure of both height and weight to calculate growth velocity in children. Height and weight must then be
recorded on a growth curve and expressed as BMI percentile positions. Height velocity should also be analysed.
42. An evaluation of pubertal development should be performed at least twice a year in peripubertal children until pubertal development is complete.
43. Patients who do not have normal growth velocity or who fall two standard deviations below their target height should have a rigorous endocrine
evaluation, which may include an assessment of the growth hormone–insulin-like growth factor-1 axis.
CF Bone Disease: Prevention Strategies
Recommendations for nutritional interventions
44. A normal body mass index with particular attention to lean body mass is important to optimize bone health.
Recommendations for control of lung infection/systemic inﬂammation
45. CF pulmonary exacerbations should be treated promptly to minimise adverse effects of systemic inﬂammation on bone.
Recommendations for vitamin D supplementation
46. All patients with vitamin D deﬁciency and insufﬁciency should be prescribed vitamin D supplements.
47. Studies are lacking to determine the most effective vitamin D supplementation regimen to correct vitamin D deﬁciency. In these circumstances, we
recommend a starting dose of 1000–2000 IU/day of vitamin D2 or D3 in infants; and a starting dose of 1000 to 5000 IU/day of vitamin D2 or D3 in
children above one year of age and in adults. The dose should then be adjusted aiming to maintain 25-hydroxyvitamin D concentration above the
deﬁciency threshold of 20 ng/ml (50 nmol/l). Current evidence favours supplementation with vitamin D3 over D2.
Recommendations for calcium supplementation
48. To maximise skeletal accretion of calcium and optimise bone health in CF, daily calcium intakes should as a minimum achieve the levels recommended
by the Food and Nutrition Board, for each age group, as following: 0–6 months: 210 mg; 7–12 months: 270 mg; 1–3 years: 500 mg; 4–8 years: 800 mg;
9–18 years: 1300 mg; 19–50 years: 1000 mg; >50 years: 1200 mg**.
49. Those with suboptimal calcium intakes should be advised to increase dietary sources of calcium. If necessary, calcium supplements can be given.
**Dietary reference intakes for calcium, phosphorus, magnesium, vitamin D, and ﬂuoride. Standing Committee on the Scientiﬁc Evaluation of Dietary
Reference Intakes, Food and Nutrition Board, Institute of Medicine. National Academy Press, Washington, D.C, 1997.
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Table 1 (continued)
Recommendations for vitamin K supplementation
50. Vitamin K supplementation is recommended for all pancreatic insufﬁcient patients.
51. Studies are lacking to determine the most effective vitamin K supplementation regimen to correct vitamin K deﬁciency. In these circumstances, we
recommend a starting dose of at least 0.5 mg to 2 mg/day in infants with CF; and a starting dose of at least 1 to 10 mg/day in children above one year of
age and adults with CF. Additional vitamin K1 supplementation may be considered in patients with low vitamin K1 levels, a prolonged PIVKA II,
increased levels of under carboxylated osteocalcin or a prolonged prothrombin time.
Recommendations for weight bearing exercise
52. Children and adolescents should be encouraged to exercise for 20–30 minutes three times a week in addition to their usual activities. Activities should
include high impact weight bearing activities such as jumping or skipping. This is likely to be most beneﬁcial in the prepubertal and early pubertal stages.
53. Adults should be encouraged to perform regular weight bearing and resistance activities. Exercise programmes should be individualised. For those not
used to doing regular exercise, the programme should begin with low impact exercises such as jogging. As ﬁtness and muscle strength improve, the
impact aspect of the programme can be increased.
54. When admitted to hospital, patients should be encouraged to continue their usual exercise programme, where possible.
CF Bone Disease: Treatment Strategies
Recommendations for the management of patients on glucocorticoids
55. The use of oral glucocorticoids should be minimised whenever possible.
56. Bisphosphonate treatment should be considered for adults taking continuous systemic oral glucocorticoids for ≥ three months with a bone mineral density
Z/T-score of −1.5 or less, and for adults who sustain a low trauma fracture while taking systemic glucocorticoids.
57. According to previous studies in non CF children, bisphosphonate treatment should be considered (in collaboration with a paediatric bone expert) for
children taking continuous systemic glucocorticoids for ≥ three months and a history of low trauma fracture and/or bone mineral density Z-score of −2
or less.
58. Bone densitometry should be performed yearly in patients prescribed continuous systemic glucocorticoids.
Recommendations for endocrine interventions
59. If sex steroid deﬁciency is suspected, it should be assessed by total and free testosterone in males, and oestradiol and sex hormone binding globulin in
females.
60. Sex steroid hormone replacement is recommended in adults with laboratory conﬁrmed sex steroid deﬁciency.
61. Growth hormone treatment may be considered (in collaboration with an endocrine specialist) in children with severe growth delay. Before growth
hormone treatment is initiated, malnutrition, malabsorption, CF-related diabetes and other causes of poor growth should be ruled out.
Recommendations for bisphosphonate treatment in adults
62. Bisphosphonate treatment should be considered in adults with CF when: a) the patient has had a low trauma fracture; and/or b) the lumbar spine or total
hip or femoral neck Z/T-score is −2 or less and there is evidence of signiﬁcant bone loss (>4% per year) on serial DXA measurements despite
optimisation of their clinical care; and/or c) the patient is awaiting or has undergone solid organ transplantation and has a BMD Z/T-score of −1.5 or less;
and/or d) the patient is starting a prolonged course of oral glucocorticoids (> three months) and has a BMD Z/T score of −1.5 or less.
63. Before prescribing bisphosphonates to adults with CF, vitamin D deﬁciency should be corrected and calcium intake must be optimised.
64. Calcium supplements should be prescribed if the patient’s dietary intake is below the recommended intake or if the plasma calcium level is low. If the
bisphosphonate preparation recommends calcium supplementation, this recommendation should be followed.
65. Patients should be counselled about the risk of osteonecrosis of the jaw and should consider seeing their dentist before starting bisphosphonate treatment
if they have signiﬁcant dental disease.
66. Oral bisphosphonates should be avoided in patients with oesophageal disease (including severe reﬂux and varices) in view of the risk of oesophageal
ulceration.
67. Oral and intravenous bisphosphonates should be used cautiously in patients with chronic renal insufﬁciency.
68. Female patients should be advised to take appropriate contraception and counselled about the risk of bisphosphonates to the unborn child before starting
bisphosphonate therapy.
69. The prescription of paracetamol, or non steroidal anti-inﬂammatory drugs, or prednisone may be considered prior to ﬁrst bisphosphonate infusion to
reduce the incidence of bone pain and ﬂu-like symptoms. Non steroidal anti-inﬂammatory drugs or paracetamol may also be prescribed prior to starting
oral bisphosphonates to reduce the incidence of ﬂu-like symptoms. These symptoms are mainly observed one to three days after the ﬁrst dose of
bisphosphonate therapy and are more common with intravenous than oral formulations.
70. Bone densitometry should be repeated after 12 months of bisphosphonate treatment to assess response and then repeated according to the algorithm in
statements 25 and 26.
Recommendations for bisphosphonate treatment in children and adolescents
71. According to previous studies in non CF children, bisphosphonates treatment may be considered after failure of optimal conservative treatment for BMD
in (a) children with CF with a BMD Z-score of −2 or less in the total body or lumbar spine and a history of low-trauma extremity fractures or vertebral
compression fractures, and (b) in children with CF awaiting or who have undergone solid organ transplantation and have a BMD Z-score of −2 or less (c)
in children with CF prescribed continuous systemic glucocorticoids and a bone mineral density Z-score of −2 or less (in collaboration with a paediatric
bone expert).
72. Bone densitometry should be repeated after approximately 6 months of treatment to assess response and then repeated according to the algorithm in
statement 24.
Recommendations for bisphosphonate treatment in transplant recipients
73. Low BMD and a history of low trauma fracture are not an absolute contraindication for lung transplant listing in people with CF.
74. Bone loss after solid organ transplantation can be lessened by the prescription of bisphosphonates in people with CF.
Recommendations for the management of rib and vertebral fractures
75. A chest X-ray should be performed to exclude pneumothorax in patients presenting with a suspected rib fracture.
76. Adequate analgesia is a priority for patients with painful rib or vertebral fractures to enable adequate chest expansion and airway clearance. If airway
clearance is compromised, intravenous antibiotics and additional mucolytic therapies may be required.
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all the cases, 25-hydroxyvitamin D levels should be measured
after completing the supplementation courses [15,16].
4.2. Interpretation of bone densitometry data
In the last decade, the measurement of bone mineral
content (BMC) and BMD in children and adolescents has
become important in both research and clinical practice.
The preferred technique for measuring BMD in younger
subjects is dual-energy X-ray absorptiometry (DXA) because
of its wide availability, low radiation dose and the ability
to measure regional BMD (lumbar spine, proximal femur
and forearm), as well as body composition. DXA also
provides good measurement reproducibility or precision –
the ability to reproduce the same numerical results in the
setting of no real biological change when the test is repeatedly
performed in an identical fashion [17]. In clinical practice,
good reproducibility is dependent on the quality of the
scanning procedure, which itself is dependent on the correct
positioning of the patient, the protocol used for analysis
and the systematic use of a calibration phantom. Precision
can be further enhanced for longitudinal BMD measurements
through using the same densitometer/ analysis software and
the same operator as for the original measurement.
However, there are also signiﬁcant technical challenges
that need to be understood when interpreting DXA data,
particularly from children and adolescents:
(1) DXA does not measure true bone mineral density
(BMC/bone volume, g/cm3), but only an “areal” bone density
(BMC/bone projection area, g/cm2). For mathematical rea-
sons, the areal BMD is inﬂuenced by bone size, and tends
to underestimate the true density value for smaller bones and
to overestimate it for larger bones. Thus, the inﬂuence of
body size must always be considered, not only for the initial
assessment, but also in the follow-up of growing patients.
Otherwise, an apparent increase in BMD may actually be
an artefact due to an increase in bone size. A widely used
correction of the vertebral “areal” BMD value obtained with
DXA aims to approximate the volumetric density, based on
the assumption that the vertebral body can be considered as
a cylinder or a cube [18,19]. This correction of the “areal”
density is called “bone mineral apparent density” (BMAD,
g/cm3). In vivo, the “volumetric” density can be more ac-
curately measured by quantitative computed tomography. It
should be noted that a deﬁnitive consensus on the best correc-
tion method has not been reached, but at a recent consensus
conference the majority of experts agreed that “in children
with linear growth or maturational delay, spine and total body
less head BMC and areal BMD results should be adjusted
for absolute height or height age, or compared to pediatric
reference data that provide age-, gender-, and height-speciﬁc
Z-scores” [20–22].
(2) DXA detects bone edges using a software algorithm
and then the projected bone area is calculated. Edge detection
algorithms designed for use in adults may not accurately de-
tect the bone edges in children with low bone mineralization.
Low-density software programs designed for use in children
are available, but these results should be compared with those
obtained with normative data also collected using low density
software [23].
(3) The choice of an appropriate reference group is
crucial for interpreting DXA data in children. The use of
inappropriate reference data (for example data collected in
children from a different ethnic group) can lead to errors in
the calculation of Z-scores. Ideally, reference data used to
evaluate BMD in growing patients should reﬂect not only the
ethnicity, gender and age of the subjects being studied, but
also body size and pubertal stage.
Finally, and above all, the clinical relevance of BMD eval-
uation is still not clearly deﬁned in children [24]. In adults,
BMD predicts the risk of osteoporotic fractures – the risk is
estimated to double for each 1 SD decrease in BMD [25].
Recent data indicate that an association between bone density
and fractures is found also in otherwise healthy children and
that low BMD is associated with increased fracture risk in the
subsequent two to ﬁve years [26–30]. Most studies [26–28,30]
evaluated only forearm fractures because of their higher preva-
lence in children and adolescents. In a study on 6,213 children
followed for 24 months, Clark et al. [29] found an association
between bone density and all appendicular fractures. How-
ever, these data need to be conﬁrmed by larger prospective
studies. It must be clearly stated that the predictive value of
low BMD for fractures remains uncertain in children, and
pediatric bone experts agree that a diagnosis of “osteoporosis”
cannot be made on the basis of BMD alone, but requires also
the presence of a signiﬁcant fracture history. According to the
recent International Society for Clinical Densitometry (ISCD)
Pediatric Position Development Conference, criteria for os-
teoporosis include low BMC or Areal BMD for age (Z-score
<−2, after adjustment for age, gender and body size) and a
clinically signiﬁcant fracture history (one long bone fracture
of the lower extremity, two long bone fractures of the upper
extremity or a vertebral compression fracture) [22]. Regarding
people with CF, the relationship between BMD and fracture
risk has not been evaluated in cross sectional or longitudinal
studies. Data from Canada suggest that BMD is a poor
predictor of fracture risk in CF adults, indicating that bone
quality may be an important determinant of fracture risk [31].
In children and adolescents with chronic diseases potentially
affecting bone, like CF, repeated DXA scans require careful
interpretation, taking into account both the physical changes
occurring during growth (in particular, paying attention to any
delay in growth or pubertal development) and the clinical
changes induced by the primary disease. As a general rule,
the repetition of a DXA scan should be considered every 1
to 2 years. In some cases a shorter time (6 months) could
be considered, for example, if a change in the clinical status
can be suspected of inducing a greater-than-expected change
in bone density. To calculate the correct interval between
scans, the least signiﬁcant changes, based on the instrument’s
and technologist’s precision, and the level of change that is
considered clinically relevant must be taken into account [23].
Regarding the age for the ﬁrst DXA scan in CF children
(statement 24), the previously published U.S. guidelines
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[5] recommended to perform it at 8 years. Some studies
demonstrated that low BMD can occur even before this age.
For example, among a cohort of 23 CF children below the
age of 6 years, Sermet-Gaudelus et al. [32] reported that 13
patients had a BMD Z-score below −1.0 SD and 7 below
−2.0 SD. Similar ﬁndings were reported by Bianchi [24].
Interestingly, in these studies low BMD was not related
to the severity of CF disease based on lung function and
nutritional parameters and low BMD was also found in
patients with a moderate lung disease and normal nutritional
status, suggesting that low BMD may be due to the intrinsic
defect, i.e. CFTR dysfunction. Since most experts in the
European working group found that bone loss is most often
observed in the peripubertal age range (8-10 years) and
fractures are infrequent in younger children, it was suggested
that screening with DXA should usually commence at the age
of 8 years.
4.3. Use of bisphosphonates in children and adolescents
Randomised controlled trials evaluating bisphosphonates
in adults with CF suggest that both intravenous and oral
formulations are effective in increasing BMD both in non-
transplant and post transplant patients. However, none of the
trials have been powered sufﬁciently to demonstrate an effect
on fracture incidence.
The use of bisphosphonates in children with CF is more
controversial because of potential long-term safety concerns
including over suppression of bone remodelling [33]. How-
ever bisphosphonates are now regularly prescribed in children
with osteogenesis imperfecta and in children with cerebral
palsy related osteoporosis, in whom recurrent fractures af-
fect quality of life and survival. Data also demonstrate the
effectiveness of bisphosphonates in children with low BMD
and fragility fractures associated with a variety of other
disorders [34]. However, due to the difﬁculties in establish-
ing the optimal dose/duration of therapy and in monitoring
the therapeutic/the long-term effects of bisphosphonates, the
prescription of bisphosphonates in children and adolescents
should always be supervised by a paediatric bone specialist.
Considering the reassuring short term (3 year) safety and
efﬁcacy data, bisphosphonate use is justiﬁed in CF children
with reduced BMD associated with low-trauma extremity
fractures and/or symptomatic vertebral compression fractures.
They may also be indicated in children awaiting solid organ
transplantation in anticipation of high dose steroid therapy
[34].
5. Conclusion
This paper presents consensus statements developed
through the EuroCareCF project that aim to harmonise clini-
cal practice and improve bone health in children, adolescents
and adults with CF. This process also highlights controversial
issues such as vitamin D supplementation regimens and the
use of bisphosphonates in children and adolescents indicating
the urgent need for therapeutic trials in this area.
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